In human prostate cancer cells, CDDO-Me inhibits the activity of p-Akt and mTOR and of their downstream targets [51,52] and overexpression of Akt leads to resistance to CDDO-Me [52]. This evidence concerns the gene AKT1 and prostate carcinoma.